Skip to main content
Figure 2 | Thrombosis Journal

Figure 2

From: Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement

Figure 2

Meta analysis on the relative risk for major bleeds in placebo-controlled trials evaluating enoxaparin or dalteparin in THR patients. The pooled relative risk for major bleeds was not significantly different between pharmacotherapy (dalteparin or enoxaparin) vs. placebo; p = 0.76. Test for heterogeneity: Chi2 = 3.34, df = 7, p = 0.85, I2 = 0.0%

Back to article page